News

Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease

On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London. Genethon is also seeking approval for this multicenter trial in Germany, Switzerland and… (read more)

Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!

The decree relating to “advanced therapy medicinal products” was published in the Journal Officiel on 8 November. A decree awaited since the adoption of the Law of 22 March 2011 allowing organizations to become non-profit pharmaceutical establishments. In the coming days, Genethon submit its application for accreditation by the… (read more)

Genethon receives the 2012 Prix Galien France

Genethon receives the 2012 Prix Galien France for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy and gene therapy.” For the first time, a non-profit organization, created by a patient association, has received the Prix… (read more)

Genethon, member of the Biotherapies Institute for Rare Diseases

The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre).

Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod

Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon.

Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director

Fulvio Mavilio, PhD is appointed as the new Scientific Director of Généthon.

Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain on January 11, 2012.

On the Internet site of the Usine Nouvelle magazine you can discover the Genethon laboratory financed by donations to the Telethon through images from behind the scenes

Both clear and comprehensive, this document will take you to the heart of gene therapy.

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS).

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

Evry (France), March 8^th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA)… (read more)

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston.

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

This agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners.

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

Innovative biotherapies and genetic eye diseases

Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon*, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome… (read more)